eligibility_summary
Include: 12–65, relapsed blood cancer after allo‑HSCT, normal liver/kidney, no hereditary disease, EF >55%, women 15–49: negative pregnancy test + contraception, consent. Exclude: extramedullary-only relapse, pregnant/lactinating, major organ failure, prior solid organ transplant, uncontrolled infection or serious illness, autoimmune/immune deficiency, systemic steroids/immunotherapy, prior immune cell therapy, recent trial/RT, investigator discretion.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05755854 (Phase 1, single-arm) tests an allogeneic Vγ9Vδ2 T-cell therapy for relapse of hematologic tumors after allo-HSCT, with fludarabine + cyclophosphamide lymphodepletion and optional zoledronic (zoredronic) acid. Drug types/mechanisms: allogeneic γ9δ2 T cells (biologic cell therapy) kill tumor cells HLA-independently by sensing phosphoantigens (IPP) via BTN3A1/BTN2A1 and stress ligands via NKG2D, mediating perforin/granzyme cytotoxicity and ADCC, fludarabine (purine analog antimetabolite) and cyclophosphamide (alkylator) deplete host lymphocytes to aid engraftment, zoledronic acid (nitrogen bisphosphonate) inhibits FPPS, raises IPP to activate/expand Vγ9Vδ2 T cells. Targets: malignant hematologic cells, mevalonate (IPP) pathway, butyrophilin (BTN3A1/BTN2A1) and NKG2D stress-ligand pathways.